Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer
NCT03789110Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Mar 2019
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in breast cancer, sponsored by Dana-Farber Cancer Institute. Started Mar 2019; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03789110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03789110.